Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Recursion Pharmaceuticals, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
FAQ
- What is Recursion Pharmaceuticals, Inc.'s EBIT?
- Recursion Pharmaceuticals, Inc. (RXRX) reported EBIT of -$134.97M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s EBIT changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s EBIT increased by 23.4% year-over-year, from -$176.23M to -$134.97M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s EBIT has grown at a 37.2% compound annual growth rate (CAGR), from -$182.78M to -$648.13M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Recursion Pharmaceuticals, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude